S
Southern Endocrinology Associates PA | Mesquite, TX
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Maridebart Cafraglutide
Evolocumab
Cadisegliatin
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 5 total trials
The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.
Active, not recruiting
Type 2 Diabetes Mellitus (T2DM)
Drug: Maridebart Cafraglutide
Drug: Placebo
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Enrolling
Diabetes Mellitus, Type 1
Drug: Cadisegliatin 800 mg QD
Drug: Placebo
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Enrolling
Obesity
Drug: Placebo
Drug: Maridebart Cafraglutide
Trial sponsors
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems